Bruker Corp. (Nasdaq:BRKR) has debuted new technologies for spatial multiomics, single-cell proteomics and cell-line, tissue and plasma proteomics cancer research. The company announced the new offerings at the American Association for Cancer Research (AACR) Annual Meeting 2022. Bruker is also building on its strategic investment in AmberGen, a Boston-based life science technology focused on photonic…